

Remarks

Applicants thank the Examiner for today's teleconference regarding the Communication, which stated that the response to Restriction Requirement filed on January 27, 2011 was allegedly non-responsive. In the teleconference, Applicants and Examiner agreed that an election of species (b) (the species comprising SEQ ID NO:22) and the cancellation of claim 19 would be a sufficient response to the Restriction Requirement mailed on September 27, 2010. Thus, Applicants hereby cancel claim 19. In addition, Applicants cancelled all other claims not directed to the elected invention (Group II) or that do not read on the elected species. Further, Applicants amended claim 10 to remove non-elected subject matter and cancelled claims 11, 48, and 91. After such amendments, claims 10, 17, and 53 are pending.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 50-4190.

Respectfully submitted,

Date: March 23, 2011



Bart W. Wise, Ph.D., J.D., Reg. No. 49,029
Attorney for Applicants

CORRESPONDENCE ADDRESS

Five Prime Therapeutics, Inc.
Two Corporate Drive
South San Francisco, CA 94080